Evidence map›Paper›PMID 27911947›Full record

ArticlePLoS pathogens2016

The Yersinia pestis Effector YopM Inhibits Pyrin Inflammasome Activation.

Dmitry Ratner, M Pontus A Orning, Megan K Proulx, Donghai Wang, Mikhail A Gavrilin, Mark D Wewers, Emad S Alnemri, Peter F Johnson, Bettina Lee, Joan Mecsas and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 127 citations in OpenAlex.

  1. ThebioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Raver1 linksProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  12. Review
  13. Review
  14. Inflammasomes and their role in PANoptosomes.Current opinion in immunology · 2024
    Review
  15. Review
  16. Article
  17. Distinct Mechanisms of Type 3 Secretion System Recognition Control LTBbioRxiv : the preprint server for biology · 2024
    Article
  18. Review
  19. Infection and immunity · 2024
    Article
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Dmitry RatnerUMass Medical School, Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, Worcester, Massachusetts, United States of America.
M Pontus A OrningUMass Medical School, Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, Worcester, Massachusetts, United States of America.
Megan K ProulxUMass Medical School, Department of Microbiology and Physiological Systems, Worcester, Massachusetts, United States of America.ORCID http://orcid.org/0000-0002-9524-8302
Donghai WangUMass Medical School, Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, Worcester, Massachusetts, United States of America.
Mikhail A GavrilinDavis Heart and Lung Research Institute, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Internal Medicine, Wexner Medical Center, The Ohio State University, Columbus, Ohio, United States of America.
Mark D WewersDavis Heart and Lung Research Institute, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Internal Medicine, Wexner Medical Center, The Ohio State University, Columbus, Ohio, United States of America.ORCID http://orcid.org/0000-0002-7079-5633
Emad S AlnemriDepartment of Biochemistry and Molecular Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.
Peter F JohnsonMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America.
Bettina LeeDepartment of Physiological Chemistry, Genentech, Inc., South San Francisco, California, United States of America.
Joan MecsasDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, United States of America.
Nobuhiko KayagakiDepartment of Physiological Chemistry, Genentech, Inc., South San Francisco, California, United States of America.
Jon D GoguenUMass Medical School, Department of Microbiology and Physiological Systems, Worcester, Massachusetts, United States of America.
Egil LienUMass Medical School, Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, Worcester, Massachusetts, United States of America.
University of Massachusetts Chan Medical School · USThe Ohio State University Wexner Medical Center · USNational Cancer Institute · USThomas Jefferson University · USTufts University · US

Funding

Technologies for Human Cellular ImmunologyU19AI057319 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LIBRATY, DANIEL H. · 2003 to 2013
$34.4M
Biology of Infectious Diseases &InflammationT32AI007538 · NIAID · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Michelle A Ozbun · 1998 to 2026
$5.2M
Macrophage Inflammasome RegulationR01HL076278 · NHLBI · OHIO STATE UNIVERSITY · PI WEWERS, MARK DAMIAN · 2005 to 2019
$4.5M
Cysteine Proteases in ApoptosisR01AR055398 · NIAMS · THOMAS JEFFERSON UNIVERSITY · PI ALNEMRI, EMAD S · 2008 to 2018
$4.2M
Innate Immunity Training ProgramT32AI095213 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SILVERMAN, NEAL · 2011 to 2025
$2.5M
Initiation and regulation of antibacterial innate immunityR01AI113166 · NIAID · TUFTS UNIVERSITY BOSTON · PI MECSAS, JOAN C · 2014 to 2018
$2.4M
Censoring Inflammation by Protein GeranylgeranylationR01AI110695 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WANG, DONGHAI · 2015 to 2019
$2.1M
NHLBI NIH HHS R01 HL076278NIAID NIH HHS R01 AI110695NIAID NIH HHS R01 AI113166NIAID NIH HHS T32 AI007538NIAID NIH HHS T32 AI095213NIAID NIH HHS U19 AI057319NIAMS NIH HHS R01 AR055398
6 · The paper itself

Abstract

Type III secretion systems (T3SS) are central virulence factors for many pathogenic Gram-negative bacteria, and secreted T3SS effectors can block key aspects of host cell signaling. To counter this, innate immune responses can also sense some T3SS components to initiate anti-bacterial mechanisms. The Yersinia pestis T3SS is particularly effective and sophisticated in manipulating the production of pro-inflammatory cytokines IL-1β and IL-18, which are typically processed into their mature forms by active caspase-1 following inflammasome formation. Some effectors, like Y. pestis YopM, may block inflammasome activation. Here we show that YopM prevents Y. pestis induced activation of the Pyrin inflammasome induced by the RhoA-inhibiting effector YopE, which is a GTPase activating protein. YopM blocks YopE-induced Pyrin-mediated caspase-1 dependent IL-1β/IL-18 production and cell death. We also detected YopM in a complex with Pyrin and kinases RSK1 and PKN1, putative negative regulators of Pyrin. In contrast to wild-type mice, Pyrin deficient mice were also highly susceptible to an attenuated Y. pestis strain lacking YopM, emphasizing the importance of inhibition of Pyrin in vivo. A complex interplay between the Y. pestis T3SS and IL-1β/IL-18 production is evident, involving at least four inflammasome pathways. The secreted effector YopJ triggers caspase-8- dependent IL-1β activation, even when YopM is present. Additionally, the presence of the T3SS needle/translocon activates NLRP3 and NLRC4-dependent IL-1β generation, which is blocked by YopK, but not by YopM. Taken together, the data suggest YopM specificity for obstructing the Pyrin pathway, as the effector does not appear to block Y. pestis-induced NLRP3, NLRC4 or caspase-8 dependent caspase-1 processing. Thus, we identify Y. pestis YopM as a microbial inhibitor of the Pyrin inflammasome. The fact that so many of the Y. pestis T3SS components are participating in regulation of IL-1β/IL-18 release suggests that these effects are essential for maximal control of innate immunity during plague.

Indexed as

AnimalsBacterial Outer Membrane ProteinsDisease Models, AnimalInflammasomesMiceMice, KnockoutPlaguePyrinYersinia pestisBacterial Outer Membrane ProteinsInflammasomesPyrinyopM protein, Yersinia

Identifiers

PMID27911947
PMCPMC5135138
OpenAlexW2557507970

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.